AlzeCure is sponsored by           


Alzecure team

AlzeCure’s multidisciplinary core team possesses key expertise from molecular target to the clinic. The team consists of senior scientists with over 85 years of combined professional experience from both small and large Pharma companies, e.g. AstraZeneca, Merck, Medivir, Biolipox, Orexo and Actar. Key members of the team have contributed to several molecules in the clinic including drugs on the market such as Ropivacaine, EMLA and Brilinta. The team has previous experience on technology transfer from the academy, establishment of start-up companies, finance and business expertise including BigPharma inlicensing and due diligence, operational and strategic competence from management- and board positions in Biotech and Pharma companies.

Johan Sandin
 In vivo pharmacology & Translational science 

Dr. Med. Sci. [Karolinska Institutet] 
Johan Sandin is a behavioral neuropharmacologist with significant international academic and industrial experience. He joined AstraZeneca in 2003 and has had scientific-, project- and senior managerial positions with responsibility for in vitro biology, in vivo pharmacology and biochemical biomarkers in the CNS research area.

Gunnar Nordvall
 Medicinal & Computational Chemistry

PhD [Uppsala University]
Previously, Dr Nordvall spent 19 years at AstraZeneca in positions of increasing responsibility, most recently as Principal Scientist in Medicinal Chemistry, where he oversaw and guided medicinal chemistry programs in the neurology and pain portfolio. He has contributed to more than 20 projects and been part of numerous scientific review committees. He has extensive knowledge and experience in both medicinal- and computational chemistry and is an expert in drug design. Dr Nordvall has served as project leader, medicinal chemistry project leader as well as manager for lead generation computational chemistry. He has more than 15 years experience in working with project generation and target evaluation, in particular for Alzheimer’s disease but also for other CNS disorders. In his background, he has a Master of Pharmaceutical Sciences degree and he received a PhD in Medicinal Chemistry from Uppsala University at the Department of Organic Pharmaceutical Chemistry.

Pontus Forsell Screening & Technology

PhD [Karolinska Institutet]
Pontus Forsell has 14 years international operational and managerial experience from biotechnology- and pharmaceutical companies such as Biolipox, Orexo, Merck and AstraZeneca. He has expertise in assay development, screening and biochemistry in several therapeutic areas such as neurology, analgesia, inflammation and respiratory diseases.

Johan Lundkvist
 Cellular screening & Neurobiology

PhD [Stockholm University]
Associate Professor Johan Lundkvist has a long academic career and is an Associate Professor at the Karolinska Institutet. He has 8 years experience of drug discovery from AstraZeneca where he has been team manager, discovery project leader and head of the Neurology externalization group.

Magnus Halldin ADMET & Regulatory Science

M.Sci. Pharm., Ph.D. [Uppsala University]
After postdoctoral studies in drug metabolism at UCSF, Magnus Halldin joined Astra in 1985, where he up to 2013 held various line and project management positions in the company, and contributed to bringing Ropivacaine and EMLA to the market. Magnus also had a scientific DMPK advisory role on numerous global scientific committees and knowledge groups, and in-licensing and due diligence opportunities within both Discovery and Development.